Sinopharm Group Co Ltd
F:X2S1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Sinopharm Group Co Ltd
F:X2S1
|
CN |
|
D
|
Dechra Pharmaceuticals PLC
F:1PK
|
UK |
|
S
|
Secom Co Ltd
XMUN:XSC
|
JP |
|
Airtel Africa PLC
F:9AA0
|
UK |
Wall St Price Targets
X2S1 Price Targets Summary
Sinopharm Group Co Ltd
According to Wall Street analysts, the average 1-year price target for X2S1 is 12.53 EUR with a low forecast of 9.33 EUR and a high forecast of 15.39 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is X2S1's stock price target?
Price Target
12.53
EUR
According to Wall Street analysts, the average 1-year price target for X2S1 is 12.53 EUR with a low forecast of 9.33 EUR and a high forecast of 15.39 EUR.
What is the Revenue forecast for Sinopharm Group Co Ltd?
Projected CAGR
5%
Over the last 14 years, the compound annual growth rate for Revenue has been 13%. The projected CAGR for the next 3 years is 5%.
What is the Gross Profit forecast for Sinopharm Group Co Ltd?
Projected CAGR
9%
Over the last 14 years, the compound annual growth rate for Gross Profit has been 12%. The projected CAGR for the next 3 years is 9%.
What is the Operating Income forecast for Sinopharm Group Co Ltd?
Projected CAGR
26%
Over the last 14 years, the compound annual growth rate for Operating Income has been 11%. The projected CAGR for the next 3 years is 26%.
What is the Pre-Tax Income forecast for Sinopharm Group Co Ltd?
Projected CAGR
10%
Over the last 14 years, the compound annual growth rate for Pre-Tax Income has been 12%. The projected CAGR for the next 3 years is 10%.
What is the Net Income forecast for Sinopharm Group Co Ltd?
Projected CAGR
10%
Over the last 14 years, the compound annual growth rate for Net Income has been 11%. The projected CAGR for the next 3 years is 10%.
